Evolus Inc

EOLS

Company Profile

  • Business description

    Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

  • Contact

    520 Newport Center Drive
    Suite 1200
    Newport BeachCA92660
    USA

    T: +1 949 284-4555

    E: [email protected]

    https://www.evolus.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    329

Stocks News & Analysis

stocks

2 ASX shares that benefit from sticky inflation

Inflation is a key risk to shareholders. Here’s why these two ASX shares benefit from higher inflation.
stocks

Our view of Dexus / Scentre deal

Dexus acquires stake in Westfiend Chermside.
stocks

Undervalued ASX retailer benefiting from rebound in spending

Uplift in sales momentum continues.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,880.6049.30-0.55%
CAC 408,106.1618.72-0.23%
DAX 4024,076.87153.04-0.63%
Dow JONES (US)48,202.97213.59-0.44%
FTSE 1009,684.7966.52-0.68%
HKSE25,235.41393.47-1.54%
NASDAQ23,052.155.26-0.02%
Nikkei 22549,383.29784.82-1.56%
NZX 50 Index13,424.9516.810.13%
S&P 5006,794.6221.89-0.32%
S&P/ASX 2008,598.9048.40-0.56%
SSE Composite Index3,824.8143.11-1.11%

Market Movers